R ibonucleoside monophosphates (rNMPs) are incorporated into genomic DNA at a frequency of one ribonucleotide per every few thousand deoxyribonucleotides due to errors in DNA polymerase action and to inherent imbalances in deoxyribonucleotide triphopshate (dNTP): rNTP pools that become more severe on treatment with certain anti-cancer drugs 1, 2 . rNMP misincorporation can give rise to mutations that pose a threat to genetic integrity 3, 4 . Accumulation of genomic rNMPs also underlies the recessive human genetic disorders Aicardi-Goutières syndrome 5 and ataxia oculomotor apraxia 1 (ref. 6 ).
At least two enzymatic activities, RNase H2 and topoisomerase I (Top1), have been found to incise rNMPs and trigger multisteprepair events 4, 7 . While RNase H2 recognizes and produces a nick 5′ to rNMPs, Top1 creates a nick 3′ to rNMPs and introduces an aberrant linkage between the 2′-hydroxyl group and 3′-phosphate group of rNMPs (2′,3′-cyclic phosphate) via nucleophilic attack of the 2′-hydroxyl group to the phosphotyrosyl bond [8] [9] [10] [11] . Top1-dependent nucleophilic attack of the 5′-hydroxyl may then reverse the process and regenerate rNMPs in biochemically reconstituted reactions 8, 9, 12 . Top1 can also induce additional cleavage a few bases from the nick and form a Top1 cleavage complex (Top1cc) similar to that found in cells treated with the Top1 poison, camptothecin (CPT) 8, 9, 11 . At short repeat sequences, secondary Top1 cleavage and ligation may produce slippage-type mutagenesis 4, 13, 14 . Unwinding and degradation of the 5′ nicks by Srs2 and Exo1 suppress Top1-mediated ligation across the gap and initiates an error-free repair 13 .
Several enzymatic activities have been implicated in the repair of Top1cc on the basis of their ability to confer cellular resistance to Top1 poisons, such as CPT, that trap Top1cc intermediates 15 . These enzymes are candidates to resolve Top1cc formed during two consecutive Top1 cleavages at rNMP-loaded genomic DNA; yet their contributions in Top1-dependent ribonucleotide removal have not been elucidated. Alternatively, 2′,3′-cyclic phosphates may represent stable intermediates in cells, and cells may depend on 3′ end-processing enzymes to remove these lesions. Using a combination of genetic and biochemical approaches, we have systematically investigated the role of 3′ end-modification enzymes for their contributions to process Top1 cleavage intermediates at genomic rNMPs. Our findings reveal that Apn2 plays a critical role in non-mutagenic Top1-dependent genomic rNMP removal and is biochemically capable of processing 3′-phosphotyrosine (pTyr)-DNA conjugates, 2′,3′-cyclic phosphates and its hydrolyzed products, specifically, terminal ribonucleotides with a monophosphate attached.
Results
Terminal phosphate adducts block the 3′ exonuclease activity from Polδ. Top1 cleaves 3′ of genomic rNMP and generates a 2′,3′-cyclic phosphate-terminated nick [8] [9] [10] . To determine whether the exonuclease activity of Polδ, the major DNA polymerase involved in DNA repair synthesis, removes the 2′,3′-cyclic phosphate or the degenerated monophosphate-terminated end, we expressed and purified Polδ complex (Pol3-Pol31-Pol32) ( Supplementary Fig. 1a ) and tested its exonuclease activity with single-stranded DNA substrates terminated at the 3′ end by either a deoxyribonucleotide, a deoxyribonucleotide bearing a 3′-phosphate, a ribonucleotide, or a nucleotide mixture of 2′,3′-cyclic phosphate and monophosphate (~40-60% of each). While robust Polδ exonuclease activity was detected on ssDNA, or ssDNA bearing a terminal ribonucleotide, a terminal phosphate group (2′,3′-cyclic phosphate and monophosphate) completely blocked the exonuclease digestion ( Fig. 1a,b) . A terminal phosphate also efficiently blocked Polδ-catalyzed extension on a primer/template duplex substrate in either the absence or presence of proliferating-cell nuclear antigen (PCNA) (Fig. 1c ). The priming site with deoxyribonucleotide termini was extended efficiently by Polδ and was stimulated by PCNA. Interestingly, the presence of a ribonucleotide at the 3′-primer terminus activated Polδ 3′-exonuclease activity and led to progressive digestion of the primer, which was partially suppressed by PCNA ( Fig. 1c ). We concluded that the terminal 2′,3′-cyclic phosphate must be processed before the Polδcatalyzed gap filling reaction.
Apn2 resolves blocked 3′ ends and suppresses Top1-induced mutagenesis at genomic rNMP sites
Fuyang Li 1,4 , Quan Wang 2,4 , Ja-Hwan Seol 1 , Jun Che 3 , Xiaoyu Lu 2 , Eun Yong Shim 3 , Sang Eun Lee 1,3 * and Hengyao Niu 2 * Apn2 processes toxic Top1 cleavage intermediates at rNMP in genomic DNA. We surmised that a 3′ nuclease may remove the terminal 2′,3′-cyclic phosphate or other adducts after Top1 cleavage at genomic rNMPs. To identify the 3′ nuclease, we used tetrad analysis to examine the growth effects of deletion of 3′ end-processing genes in RNH201 deletion strains that express mutant DNA polymerase (pol2-M644G). In comparison to wild type, the mutant Polε incorporated about tenfold more rNMPs during DNA replication due to its reduced ability to discriminate rNTPs from dNTPs 7 . Deletion of RNH201 channels rNMP removal towards the Top1dependent pathway 4, 16 . Since srs2∆ is synthetic lethal with pol2-M644G rnh202∆ 13 , a defect in processing 3′ blocked ends probably impairs cell growth following Top1 cleavage at rNMP, and, most importantly, the growth defect should be fully offset by TOP1 deletion. Previously, Apn1, Apn2, Tpp1, and Rad1/Rad10 have been implicated in processing 3′ blocked DNA termini under alkylating or oxidative conditions [17] [18] [19] . Tdp1, Mre11, Slx4, and Rad1/Rad10 are also implicated in processing Top1cc on treatment with the Top1 poison, CPT [20] [21] [22] . One or more of these nucleases are candidates for 3′ end processing in rNMP repair. We also monitored the sensitivity of yeast strains to hydroxyurea treatment 7 , as the inhibition of ribonucleotide reductase by hydroxyurea raises the cellular rNTP/ dNTP ratio and increases genomic ribonucleotide incorporation 23 .
We found that deletion of APN1, RAD1, SLX4, TDP1, TPP1 caused no apparent growth changes in pol2-M644G rnh201Δ mutant cells nor sensitivity to hydroxyurea treatment ( Supplementary  Fig. 2a -e and data not shown). We also found that pol3-01, a proofreading defective mutation, did not affect the viability of pol2-M644G rnh201Δ cells ( Supplementary Fig. 2f ), indicating that the proofreading nuclease activity of Polδ does not process 3′ blocked ends. Deletion of RAD1 in pol2-M644G rnh201Δ mutant showed moderate sensitivity to a low dose hydroxyurea treatment ( Supplementary  Fig. 2i ). However, deletion of TOP1 enhanced rather than reduced the hydroxyurea sensitivity of pol2-M644G rnh201Δ rad1Δ mutants, indicating that hydroxyurea sensitivity is not due solely to a defect in repairing blocked 3′ ends during Top1-catalyzed rNMP removal. Previously, deletion of TDP1 or RAD1 alone did not confer sensitivity to CPT treatment due to their functional redundancy in resolving Top1cc 19, 20 . The deletion of both RAD1 and TDP1, however, did not lead to Top1-dependent growth defects nor hydroxyurea sensitivity ( Supplementary Fig. 2g ,i). We also found that deletion of MRE11 is lethal in pol2-M644G rnh201Δ mutant in tetrad analysis, but deletion of TOP1 did not restore viability ( Supplementary Fig. 2h ).
Unique among the nucleases examined, deletion of APN2 is synthetic lethal to pol2-M644G rnh201Δ as seen in srs2∆ ( Fig. 2a) 13 . Importantly, viability is fully rescued by the concomitant deletion of TOP1 ( Fig. 2a ). Expression of Top1 from a galactose-inducible promoter caused lethality in pol2-M644G rnh201Δ apn2Δ top1Δ cells ( Fig. 2b) . Expression of the nuclease-deficient apn2-E59A is lethal in pol2-M644G rnh201Δ apn2Δ (Fig. 2c ). Deletion of APN2 is also lethal in pol3-L612G rnh201Δ mutant that frequently incorporates rNMPs during lagging strand DNA synthesis 24 (Fig. 2d ). Importantly, APN2 deletion in rnh201Δ mutants did not increase the level of alkali labile rNMPs in DNA, monitored by denaturing agarose gel electrophoresis ( Supplementary Fig. 3a ), and purified Apn2 protein does not react with duplex DNA with a single embedded rNMP ( Supplementary Fig. 3b ). Apn2, therefore, does not directly remove rNMPs from DNA but probably acts as the major end-healing enzyme to facilitate Top1-catalyzed rNMP repair.
Apn2 processes 2′,3′-cyclic phosphate-terminated ends. We next examined biochemically the processing of the terminal 2′,3′-cyclic phosphate by the purified recombinant 3′ cleaning enzymes, Apn1, Apn2, and Tpp1 ( Supplementary Fig. 1d ,e). To create a DNA substrate with a pure 2′,3′-cyclic phosphate-terminated nick, duplex DNA with a single embedded ribonucleotide 12 nucleotides (nt) away from the 5′ end was treated with top1-T722A, a ligationdefective Top1 mutant that produces nearly threefold more cyclic phosphate-terminated ends than wild type Top1 25 ( Supplementary  Fig. 3c ). Polynucleotide kinase (PNK), but not calf-intestinal alkaline phosphatase (CIP), can remove 2′,3′-cyclic phosphate from a terminal ribonucleotide 8, 26 , and we confirmed that only PNK removed the terminal 2′,3′-cyclic phosphate from the substrate ( Fig. 3a) . Strikingly, Apn2, a far less active apurinic/apyrimidinic endonuclease compared with Apn1 ( Supplementary Fig. 3d ), removed a dinucleotide from the 2′,3′-cyclic phosphate-terminated end and generated a 10-nt-long species (Fig. 3a ). Since the additional cyclic phosphate causes the 12-nt oligonucleotides to migrate near the 11-nt position, we further treated the Apn2 digestion products with PNK, but did not observe an 11-nt product. Thus, the observed band after Apn2 treatment represents a dinucleotide cleavage product ( Fig. 3a) . In contrast, neither apn2-E59A, Apn1, or Tpp1 reacts with the terminal 2′,3′-cyclic phosphate ( Fig. 3a and Supplementary  Fig. 3e ). A similar dinucleotide removal was also observed at the 2′,3′-cyclic phosphate-terminated end generated by RNase I f (Fig. 3b ). In the same reaction, we also detected a 12-nt species, probably derived from removal of the terminal monophosphate by Apn2. To confirm this observation, 5′ overhang DNA substrate harboring various 3′ termini-a clean deoxyribonucleotide, a deoxyribonucleotide with 3′-phosphate, a clean ribonucleotide or a monophosphate-attached ribonucleotide (synthesized by IDT)were further tested. The results showed that Apn1, Apn2, and Tpp1 are end-modification enzymes with minimal 3′ exo/endonuclease activities toward a 3′ end with a clean nucleotide ( Fig. 3c ). Interestingly, Apn2 is able to remove the monophosphate attached to a ribonucleotide ( Fig. 3c ) but not to a deoxyribonucleotide ( Fig. 3c ), while both Apn1 and Tpp1 are capable of removing monophosphate attached to either a deoxyribonucleotide or a ribonucleotide ( Fig. 3c ). Since terminal cyclic phosphate is a relatively unstable intermediate that may be hydrolyzed to monophosphate in cells, the end-cleaning activities of Apn2 are highly specific to 2′,3′-cyclic phosphate-related adducts. Apn2 could also remove 2′,3′-cyclic phosphate and monophosphate at terminal ribonucleotides on both 5′ overhang and nicked duplex substrates, with similar efficiency, but not on a single-stranded substrate ( Supplementary  Fig. 3f ). Thus, Apn2 preferentially removes a 3′ adduct from terminal ribonucleotides, consistent with its role in end repair during rNMP cleavage by Top1.
PCNA stimulates exonuclease activity of Apn2 on 2′,3′-cyclic phosphate-terminated ends. PCNA physically interacts with Apn2 and stimulates both its 3′ → 5′ exonuclease and 3′ phosphodiesterase activities on a deoxyribonucleotide-terminated 3′ end 27 . We therefore examined the effect of PCNA on terminal 2′,3′-cyclic phosphate removal by Apn2. To retain PCNA on the substrate DNA molecules, we constructed 5′ overhanging duplex DNA that allow both ends to be occluded by biotin-bound streptavidin ( Supplementary Fig. 4a ).
In the presence of streptavidin, the 3′ → 5′ exonuclease activity of Apn2 was apparent on a clean, recessed 3′ DNA end on loading of PCNA ( Supplementary Fig. 4a ). End occlusion of the 5′ overhang side can also be achieved by addition of single-stranded DNA binding proteins RPA or Escherischia coli SSB ( Supplementary Fig. 4a ). PCNA also stimulated Apn2 degradation of 3′ termini with a clean ribonucleotide or a ribonucleotide with a monophosphate attached ( Supplementary Fig. 4b ). Importantly, PCNA stimulated Apn2, but not apn2-E59A, in the digestion of the 2′,3′-cyclic phosphateterminated nicked duplex ( Fig. 4a ). Apn2, but not apn2-E59A, also enabled primer extension by Polδ from a 2′,3′-cyclic phosphateterminated priming site. We note that these reactions contain only dATP, dGTP, and dTTP to constrain extension to six nucleotides, allowing us to discriminate primer extension products from the full length substrate molecule. The extension products are resistant to alkaline (NaOH) treatment ( Fig. 4a ), indicating that the terminal ribonucleotide has been removed. The presence of Exo1, while having minimal effect on Apn2-catalyzed cleavage, improved the Polδ extension reaction. While PCNA stimulates Apn2-catalyzed initial clipping at the 2′,3′-cyclic phosphate-terminated end by three-to sixfold at 30 °C (Fig. 4b ), a similar reaction at 16 °C clearly revealed early cleavage products, which, following PNK treatment, showed an intermediate corresponding to a dinucleotide removal ( Fig. 4c ). Thus, exonucleolytic digestion by Apn2-PCNA probably occurs after removal of the initial dinucleotide. Apn1 and Tpp1 cannot substitute Apn2 for the observed exonuclease activity on a 2′,3′-cyclic phosphate-terminated end ( Supplementary Fig. 4c,d) , and fail to support Polδ-catalyzed extension ( Supplementary Fig. 4c,d ). PCNA also improves the exonuclease activity of Apn2 ( Supplementary  Fig. 4e ) and enables Polδ to extend a terminal ribonucleotide with a monophosphate ( Supplementary Fig. 4e ). In control assays, Polδ-PCNA was able to extend from a clean terminal ribonucleotide ( Supplementary Fig. 4f ) with minimal effects of addition of Apn2. Thus, the ability of Apn2 to promote Polδ-catalyzed repair synthesis is adduct specific.
Role of 3′ end processing in Top1-induced mutagenesis.
Evidence suggests that Top1-dependent cleavage at ribonucleotides induces an increase in 2-5-bp slippage mutation events, which is apparent in RNase H2 deletion mutants 4, 13 . A secondary Top1 cleavage less than six nucleotides from the initial Top1 cleavage site, followed by ligation across a 2-5-bp gap, could account for these mutations. Since tdp1∆ and apn2∆ led to a modest increase of slippage mutation rate in rnh202∆ 14 , we examined the effect of APN2 gene deletion on Top1-induced mutagenesis in wild type and tdp1 deleted cells using the lys2ΔA746(AG) 4 frameshift reversion assay, which detects 2-to 5-bp deletion events 4, 13 (Fig. 4d ). The effect of APN1 deletion was also measured as a control. Deletion of APN1, APN2, or TDP1 in strains with functional RNase H2 did not alter lys2 reversion frequency ( Fig. 4d ). Analysis of reversion frequencies indicated that the 2-5-bp slippage events at the Top1 hotspot correspond to 36% in the apn2 single gene deletion mutant (Supplementary Table 1 ). As expected, deletion of rnh201 led to a dramatic increase (75-fold) in the frequency of lys2 reversion that was dependent on TOP1 (Fig. 4d ). Analysis of the mutation spectrum revealed that 94% of these mutations are 2-bp deletions at the Top1 consensus site (Supplementary Table 1 ). Deletion of APN2, but not APN1, in a rnh201 mutant strain increased the lys2 reversion frequency 143-fold ( Fig. 4d ). Deletion of TDP1 in rnh201 also increased 2-bp deletions among lys2 revertants (103-fold). Most importantly, deletion of both APN2 and TDP1 in rnh201 further increased lys2 reversion frequency higher than that observed in apn2 rnh201 or tdp1 rnh201 cells (232-fold). Over 90% of the reversion events in all these mutants were 2-bp deletions at the Top1 consensus site ( Supplementary Table 1 ). Taken together, these results suggest that Apn2 and Tdp1 represent two distinct mechanisms that suppress slippage mutagenesis after Top1 cleavage at genomic rNMPs.
Apn2 processes Top1cc intermediates in vitro. The synthetic phenotype of apn2∆ and tdp1∆ on slippage mutagenesis prompted us to ask whether Apn2 could process Top1cc. Although deletion of APN2 alone, or APN2 and TDP1, does not render cells sensitive to CPT treatment ( Fig. 5a and data not shown), deletion of APN2, but not APN1, in TDP1-and RAD1-deleted cells severely impaired growth and showed sensitivity to CPT treatment that is far more severe than that of TDP1 RAD1-deleted cells (Fig. 5a ). Deletion of TOP1 completely restored growth of mutant yeast to levels only slightly less than those seen in strains without cognate gene deletions (Fig. 5a ). Interestingly, while Apn2 does not remove 3′-phosphate attached to the DNA end ( Fig. 3c Degradation products RFC-PCNA 20 20 + top1-T722A 20 20 T4-PNK(10U) 26 harboring a 3′-phosphotyrosine (pTyr) (Fig. 5b) , an activity that is not observed with either apn2-E59A or Apn1. Unlike Tdp1, which leaves a 3′-phosphate, Apn2 generates a clean 3′-OH end that can be directly modified by terminal transferase to attach a radiolabeled nucleotide (Fig. 5c ). However, Apn2 is unable to process the 3′-PO 4 adduct generated by Tdp1 (Fig. 5d ), consistent with prior assays (Fig. 3c ). PCNA also stimulates pTyr removal by Apn2, which enables Polδ-catalyzed extension of the 3′-pTyr blocked primer end (Fig. 5e ). These results suggest that Apn2 may resolve Top1cc and produce 3′ termini suitable for DNA synthesis.
5′ DNA gap limits Top1-dependent mutagenesis. Cleavage by eukaryotic topoisomerase I relies on duplex regions flanking the cleavage site 28 . Hence, gap generation by Srs2/Exo1 could shunt repair to pathways that depend on terminal 2′,3′-cyclic phosphate processing rather than secondary Top1 cleavage. Thus, inhibition of 5′ gap formation might bypass the importance of Apn2-dependent 2′,3′-cyclic phosphate processing. Deletion of EXO1 or SRS2 indeed increases lys2 reversion rate 13 . Most importantly, deletion of EXO1 partially restored the viability of pol2-M644G rnh201∆ apn2∆ strain (Fig. 6a ). To directly test whether a 5′ gap determines the type of end repair, we examined the secondary cleavage by Top1 on either a 5′ overhang duplex or a nicked duplex substrate bearing a mixture of terminal 2′,3′-cyclic phosphate and monophosphate. Consistent with prior reports 28 , minimal cleavage by Top1 was observed on a 5′ overhang duplex (Fig. 6b) , while SDS-resistant Top1cc was detected in the reaction with the nicked duplex substrate. Proteinase K treatment of Top1cc products yielded a series of peptide-DNA conjugates corresponding to secondary cleavage by Top1. An alkaline-resistant ligation product resulting from Top1-catalyzed ligation following secondary cleavage was also observed (Fig. 6b) 8 . Hence the formation of a 5′ DNA gap may dictate the type of 3′ end processing and the level of slippage mutagenesis following Top1-catalyzed cleavage at rNMP sites. Notably, the purified peptide-DNA conjugates derived from Top1cc can be processed by Apn2 to yield clean 3′-OH ends, which reinforces the role of Apn2 in Top1cc removal (Fig. 6c ).
Discussion
Blocked 3′ ends, including protein-DNA conjugates, damaged bases, and oxidation of replication forks, arise from a wide range of cellular events 20, 29, 30 . The blocked 3′ end, if not processed, could interfere with downstream enzymatic processes and thus be lethal or mutagenic. Herein, we discovered that Apn2 is specialized to remove multiple types of 3′ adducts on the DNA terminus, particularly those associated with Top1 cleavage at genomic rNMPs 7, 16 . We also analyzed the biochemical attributes of Apn2 in processing 3′ ends blocked by phosphate or peptide adducts. Our findings reveal a role of Apn2 in genome maintenance and mutation avoidance, and shed light on the types of genome stability associated with various blocked 3′ ends produced following Top1 cleavage at rNMPs in yeast. Apn2 was originally identified as a back-up apurinic/apyrimidinic endonuclease to Apn1 (refs. 31, 32 ). Subsequent studies, however, uncovered 3′ nuclease and phosphodiesterase activities of Apn2, which are stimulated upon its binding to PCNA 27, 29, 30 . Using biochemical approaches, we have discovered several new Apn2 substrates. Our results suggest that Apn2 is uniquely capable of removing pTyr-DNA conjugates to generate 3′-hydroxyl ends that are substrates for DNA synthesis and ligation without further modification steps. This activity contrasts with that of Tdp1, whose cleavage produces yet another blocked 3′-phosphate end that requires Tpp1dependent processing 33 . Interestingly, the 3′-phosphate generated by Tdp1 is resistant to Apn2. Thus, Apn2 and Tdp1-Tpp1 probably function as independent pathways in Top1cc removal. Furthermore, the presence of a terminal 2′,3′-cyclic phosphate, but not a monophosphate, triggers Apn2 nuclease to remove two terminal nucleotides from the 3′ end. Taken together, we have demonstrated that Apn2 is a highly versatile nuclease against a diverse set of 3′ blocked ends. Enzymatic activities of Apn2 are probably modulated according to the types of substrates and interacting proteins to optimize their functions under different physiological conditions.
Our results show that apn2∆ is synthetic lethal with pol2-M644G rnh201∆ in a Top1-dependent manner, indicating that Apn2 plays a pivotal role in Top1-dependent rNMP removal. Since purified Apn2 processes both Top1cc and 2′,3′-cyclic phosphate termini, the essential function of Apn2 is probably derived from processing one or both types of adducts. Several lines of evidence suggest that the 2′,3′-cyclic phosphate, and not the Top1cc, is the lesion responsible for the lethality observed in pol2-M644G rnh201∆ apn2∆. First, Top1cc can be removed by enzymes other than Apn2, such as the Tdp1/Tpp1 pathway. However, deletion of TDP1 or TPP1 does not impair viability of pol2-M644G rnh201∆ cells. In contrast, Apn2 is uniquely capable of removing the terminal 2′,3′-cyclic phosphate. Second, the synthetic lethality of apn2∆ or srs2∆ in pol2-M644G rnh201∆ suggests that Srs2 and Apn2 might operate at two different ends of the same intermediate, where the deletion of EXO1, which functions with Srs2 helicase in gap generation, partially offsets the lethality of pol2-M644G rnh201∆ apn2∆ mutant 13 . Alternatively, we surmise that the terminal 2′,3′-cyclic phosphate may be removed by Apn2 or by Top1-catalyzed secondary cleavage 8, 9, 12 Fig. 6 | exo1∆ suppresses the lethality of pol2-M644G rnh201Δ apn2Δ. the 2′,3′-cyclic phosphate from a gapped DNA. Deletion of EXO1 may allow cells to use these other options, rendering the Apn2 pathway partially dispensable for end processing in Top1-mediated rNMP removal. These results suggest that Srs2/Exo1-mediated gap formation may act as the default pathway, and that secondary Top1 cleavage operates only when 5′ gap formation is defective or not yet initiated.
Although Tdp1 does not process the 2′,3′-cyclic phosphate-terminated end, it plays a role in the avoidance of slippage mutations, presumably through the removal of Top1cc following the second Top1 cleavage ( 14 and Supplementary Fig. 5 ). apn2∆ also led to an increased slippage mutation rate, which may be attributed to the activity of Apn2 in Top1cc removal. Alternatively, Apn2-catalyzed 2′,3′-cyclic phosphate removal might suppress slippage mutagenesis by inhibiting Top1 cleavage because the presence of a terminal 2′,3′-cyclic phosphate at a nick stimulates Top1-catalyzed secondary cleavage 8 . Taken together, our results suggest that 5′ gap formation could dictate the type of blocked 3′ end processing and thereby modulate repair outcomes and the associated mutagenesis ( Supplementary Fig. 5 ).
We discovered that PCNA stimulates the ability of Apn2 to remove a terminal 2′,3′-cyclic phosphate via dinucleotide cleavage. Intriguingly, apn2-∆PIP, a PCNA interaction-deficient variant, fully supports viability of pol2-M644G rnh201∆ cells and does not alter the frequency of Top1-dependent slippage mutagenesis (Supplementary Table 1 and data not shown). These results challenge the requirement for PCNA-dependent stimulation of Apn2 in Top1-mediated rNMP removal. We note, however, that a previous study 27 suggested two different modes of binding between Apn2 and PCNA that depend on whether PCNA is loaded onto DNA. The PIP box motif in Apn2 is largely responsible for the interaction between Apn2 and DNA-free PCNA, which may explain the moderate defect of the apn2-PIP mutant in PCNA-stimulated 3′ digestion. Similar to prior reports 27 , the stimulation of Apn2 on 2′,3′-cyclic phosphate end processing observed in our system also requires DNA-bound PCNA (data not shown). Most recently, another PCNA-binding domain of Xenopus Ape2 was identified that promotes exonuclease activity by Ape2 34 . More detailed analyses of PCNA-interacting interfaces and their contributions to Apn2 activities will help determine the nature of Top1-induced blocked 3′ ends and their cellular levels.
Apn2 is an evolutionarily conserved nuclease with homologs found from bacteria to human cells 31, 35, 36 . APE2 (the mammalian Apn2 homolog) knockout mice exhibit growth retardation and mild dyslymphopoiesis 37 . APE2 deficiency also leads to defects in class switch recombination 38 . In mammals, APE2 activates Chk1 by degrading DNA and generating single-stranded DNA at sites of oxidative damage 35, 39 . However, the basis of this host of symptoms and phenotypes in APE2-deleted cells and organisms is not yet known. It will be important to test whether APE2 has equivalent functions in healing 3′ blocked ends in mammals and whether some of the defects associated with APE2 deficiency could be attributed to elevated genome instability caused by the lack of enzymatic activities we have elucidated here. Supplementary Table 2 . Gene deletions were created by transforming drug-resistant, PCR-derived DNA fragments of the KANMX, CLONAT, HYGROMYCIN B, or PCR-derived, yeast metabolic marker genes URA3, TRP1, or HIS3 into the corresponding strains. Gene sequence-specific mutation was generated by two-step transformation as described 40 . Genomic mutations were verified by PCR and restriction digestion, and DNA sequencing. lys2 reversion assays. The Lys + rate in lys2ΔA746NR(AG)4 reporter cells was determined as described previously 4, 13 . At least 12 independent cultures per isolate (2 to 3 independent isolates per genotype) were used to determine the rates, and 95% confidence intervals were determined in fluctuation assay. Lys + colonies (40 to 120) growing on lysine dropout plate were randomly chosen to verify the types of mutations by sequencing the region flanking the (AG) 4 repeat. Primers (5′-AGTTTTTCTAACAAATACGCTGTCG-3′ and 5′-CGCATTATTACTGGTATCCAAATTC-3′) were used to amplify the region flanking the inserted (AG) 4 repeat.
Methods

Strains. Strains used for the experiments are listed in
Drug sensitivity assay. Yeast cells with the indicated gene deletion or mutation were cultured in yeast extract peptone dextrose (YEPD) medium for 24 to 36 h to reach the density of ~1 × 10 8 cells per ml, ~2 × 10 6 cells were transferred to 200 μl sterilized distilled water, and applied to 1:5 serial dilution. Cells with different density were spotted onto YEPD agar plates with the indicated concentration of CPT and kept at 30 °C for 48 to 72 h.
Expression and purification FLAG-His6-Top1 and FLAG-His6-top1-T722A
from insect cells. The Top1 coding sequence was PCR amplified from yeast genomic DNA (S288C) and cloned into a modified pFASTBac-HTB vector 41 and fused in frame to the FLAG and His 6 tags in this vector. Using this construction, a bacmid was generated from the E. coli strain DH10Bac (Invitrogen) to express Top1 in insect cells. For Top1 purification, The insect cell pellet (~15 g from 1 l culture) was resuspended in 100 ml of K buffer (20 mM KH 2 PO 4 , pH 7.4, 10% glycerol, 0.5 mM EDTA, 0.01% NP-40, 1 mM DTT) with a cocktail of protease inhibitors (aprotinin, chymostatin, leupeptin, and pepstatin A at 5 μg ml −1 each, and also 1 mM phenyl-methylsulfonyl fluoride) and 500 mM KCl. Cells were disrupted by sonication for 30 s, and the lysate was clarified by centrifugation (20,000g for 20 min). The supernatant was filtered through Whatman glass microfiber filter (GE Healthcare) and loaded onto a 3 ml Ni-NTA column (ThermoFisher) using a Bio-Rad Econo pump. The column was washed with 60 ml K buffer containing 500 mM KCl and 15 mM imidazole. Top1 was eluted with 20 ml K buffer containing 500 mM KCl and 200 mM imidazole. The eluate was further incubated with 0.5 ml anti-FLAG M2 agarose resin (Sigma) for 2 h. The matrix was washed 40 ml K buffer containing 500 mM KCl and 0.1% NP-40 before Top1 was eluted with 1 ml of K buffer containing 200 μg ml −1 FLAG peptide. The eluate was filter dialyzed to remove excess FLAG peptide, further concentrated in an Ultracel-30K concentrator (Amicon). The purified Top1 protein (~50 μg) was frozen in liquid nitrogen and stored at −80 °C as small aliquots. To express top1-T722A, T722A mutation was introduced via site-directed mutagenesis. The mutant protein was expressed and purified similarly to wild type Top1 with a slightly better yield (~100 μg). 6 tagged Apn1, Apn2, Tdp1, and Tpp1 from E. coli. To express, purify, and systematically characterize 3′ adduct cleaning enzymes (Apn1, Apn2, Tdp1, and Tpp1), DNA fragment encoding individual enzymes was amplified from yeast genomic DNA (S288C) and fused in frame to the His 6 tag in pETDuet1. These four enzymes were expressed in E. coli and purified similarly. For their expression, BL21-codon plus strain was transformed with the respective expression vector. An overnight culture was diluted 1:50 into 12 litres LB medium containing 100 mg l −1 ampicilin and 37 mg l −1 chloramphenicol. Expression of the target protein was induced overnight at 16 °C with 0.2 mM IPTG added when the culture reached A 600 = 0.8. Cells were collected via centrifugation, which yields a 60 g or so cell pellet for each protein expressed. For their purification, the respective cell pellet was resuspended in 240 ml of K buffer containing 150 mM KCl and lysed by sonication (eight times of 15 s with 15 s pulse in between). After sample clarification by centrifugation (20,000g), the lysate was loaded onto a 5 ml SP sepharose column. The column was washed with 100 ml K buffer plus 150 mM KCl before it was developed with a 100 ml linear gradient from 150 to 575 mM KCl. The fractions containing the target protein were pooled and incubated with 0.5 ml of Ni-NTA resin (ThermoFisher) for 2 h. The matrix was washed with 30 ml K buffer with 500 mM KCl and 15 mM imidazole. The target proteins were then eluted with K buffer containing 500 mM KCl and 200 mM imidazole. The eluate was filter dialyzed to remove excess imidazole using either Ultracel-10K or Ultracel-30K concentrator according to the target protein's molecular weight. The purified proteins were further concentrated, frozen with liquid nitrogen, and stored at 80 °C. This procedure yields ~100 μg of Apn1, ~100 μg of Apn2, ~500 μg of Tdp1, and ~1 mg of Tpp1. The full length of His 6 -Apn2 is subjected to proteolysis at its carboxyl terminus. Thus, the yeast expression system is further employed to express and purify Apn2.
Expression and purification of N-terminal His
Expression and purification of Apn2-FLAG from S. cerevisiae. For yeast expression of Apn2, the coding region of APN2 was cloned between the Not1 and SpeI sites in pESC-URA (Agilent), placing the gene under the control of the GAL10 promotor with a FLAG tag fused to the carboxyl terminus of APN2. Apn2 protein was expressed in the protease-deficient yeast strain 334 (MATα pep4-3 prb1-1122 ura3-52 leu2-3,112 reg1-501 gal1). For Apn2 expression, an overnight culture was diluted 1:50 into 12 l of -ura omission medium with 2% glucose. Cells were cultured at 30 °C until the A 660 reached 0.8, at which time galactose was added to reach 2% final concentration to induce Apn2 expression. Cells were collected by centrifugation after 12 h of further incubation, and the pellet (50 g) was stored frozen at −80 °C. After grinding the yeast pellet with dry ice, 50 ml of K buffer (20 mM KH 2 PO 4 , pH 7.4, 10% glycerol, 0.5 mM EDTA, 0.1% NP-40, 1 mM β-mercaptoethanol) with a cocktail of protease inhibitors (aprotinin, chymostatin, leupeptin, and pepstatin A at 5 μg ml −1 each, and also 1 mM phenyl-methylsulfonyl fluoride) and 150 mM KCl was added to the extract. All the subsequent steps were carried out at 0-4 °C. The extract was clarified by centrifugation (20,000g for 20 min) and then applied onto a 5 ml column of SP agarose (GE). The column was washed with 100 ml K buffer with 150 mM KCl. Apn2 was eluted with 30 ml of K buffer with 500 ml KCl, and the eluate was mixed gently with 0.4 ml anti-FLAG-M2 resin for 2 h. After washing the matrix with 30 ml of K buffer with 500 mM KCl and 0.1% NP-40 and 10 ml of K buffer with 500 mM KCl, Apn2 was eluted with 1.5 ml of K buffer plus 500 mM KCl and 200 μg ml −1 FLAG peptide for 1 h. The eluate that contained purified Apn2 was filter dialyzed and concentrated using an Ultracel-30K concentrator (Amicon) to 1 mg ml −1 and stored at −80 °C in aliquots. The overall yield of Apn2 was ~100 μg.
The apn2-E59A point mutation was introduced into pESC-URA-APN2 vector by site-directed mutagenesis and the mutant was expressed and purified similarly to wild type. The yield of apn2-E59A was lower than that of wild type (~5 μg from 12 l culture).
Yeast DNA Polδ, replication factor C, PCNA, RNase H2, and replication protein A. The yeast DNA polymerase δ complex, containing FLAG-Pol3, GST-Pol31, and Pol32, was expressed in yeast protease-deficient strain BJ5464 (MATα pep4::HIS3 prb1∆1.6R ura3-52 trp1 leu2∆1 can1 GAL) using pBJ1445 and pBJ1524. Purification was conducted similarly as described 42 . Replication factor C (RFC) complex (Gst-Rfc1, Rfc2, Rfc3, Rfc4, Rfc5) was also expressed in yeast strain BJ5464 using pBJ1476 (2 µ, GAL-PGK-GST-RFC1/RFC4/RFC5, LEU-2d) and pBJ1469 (2 µ, GAL-PGK-RFC2/RFC3, TRP1) and purified similarly as described 42 . PCNA was expressed in E. coli using pQE16-Pol30 and purified similarly as described 42 . RNase H2 complex was affinity purified from a yeast strain from the 'Yeast GST Fusion Collection' (Horizon/Dharmacon), where the GST tag is fused in frame at the N terminus of Rnh201. Single-strand DNA-binding protein (RPA) was expressed in yeast and purified similarly as described before 43 .
DNA substrates. Generating 2′,3′-cyclic phosphate-terminated substrates. Oligonucleotides used to construct substrates for biochemical assays are listed in Supplementary Table 3 . To generate 2′,3′-cyclic phosphate-terminated nicked duplex, duplex DNA with a single embedded ribonucloetide was treated with top1-T722A, a ligation-defective mutant of Top1 that generates about threefold more cyclic phosphate-terminated nicks compared with wild type Top1 ( Supplementary Fig. 3c ). Using duplex DNA from annealing H1 to H2 and H3 to H4, two nicked duplex substrates were created with a DNA fragment harboring 2′,3′-cyclic phosphate ends 12 nt and 27 nt in length, respectively. To generate partially 2′,3′-cyclic phosphate-terminated oligonucleotides to test exonuclease activity of Polδ and Apn2 nuclease activity on different structured DNA, a 14-ntlong oligonucleotide (H5) with two consecutive ribonucloetides and a protective deoxyribonucleotide at the 3′ end was partially digested by RNase I f (New England Biolabs) for 5 min at 37 °C, which yields ~40-60% of 2′,3′-cyclic phosphateterminated ends that are resistant to alkaline phosphatase (New England Biolabs).
DNA substrates with other end structures.
Oligonucleotides with a terminal deoxyribonucleotide (H6 and H7), a terminal 3′-phosphate (H8 and H9), a terminal ribonucloetide (H10 and H11) were purchased from IDT. Oligonucleotides with a 3′-pTyr adduct (H12 and H13) were synthesized by Midland. To create respective 5′ overhanging with a 12-bp or 27-bp duplex region, H6, H8, H10, or H12 were annealed to H1; and H7, H9, H11, or H13 were annealed to H3. H14 was added to the respective annealing reaction to create the corresponding nicked duplex substrates. To block one end of the H3-containing duplex, biotin was engineered to the 3′ end of H3 to give the oligonucleotide H15.
Apn2 nuclease assays. For Apn2 nuclease assays, unless specified, DNA substrate (10 nM) was incubated with the indicated amount of Apn2 in the reaction buffer (20 mM Tris-HCl, pH 8.0, 2 mM MgCl 2 , 1 mM DTT, 200 ng ml −1 BSA, 50 mM KCl) for 10 min at 30 °C. Reaction involving PCNA was conducted in a similar reaction buffer except the concentration of KCl was raised to 100 mM. The reaction was stopped by treatment with SDS (0.2% final) and proteinase K (0.5 mg ml −1 ) for 10 min at 37 °C. Equal volume of loading dye containing 85% formamide with 25 mM EDTA, and 1 µM unlabeled H1 (ribo-containing strand) was then added to reaction mixtures, preventing the re-annealing of the radiolabeled H1 to its complementary strand. The mixture was heated at 95 °C for 5 min before being fractionated in a 19% or 12% denaturing polyacrylamide gel in TBE (Tris-boric acid-EDTA) buffer for 12 nt or 27 nt substrate, respectively, and followed by phosphorimaging analysis. Other nucleases (Apn1, Tdp1, Tpp1) were assayed similarly.
Polδ extension assays. The 2′,3′-cyclic phosphate-terminated nicked duplex was made as described above. In brief, 20 nM duplex DNA with a single ribonucleotide embedded was incubated with 10 nM yeast Top1-T722A for 10 min at 30 °C in 10 µl buffer (20 mM Tris-HCl, pH 8.0, 2 mM MgCl 2 , 1 mM DTT, 100 μg ml −1 BSA, 100 mM KCl, 1 mM ATP). We note that either 0.1 mM of each of the four dNTPs were added to the reaction to allow full extension by Polδ, or only dATP, dGTP, and dTTP were added to trap a 6-nt-long extension product for quantification purposes. Following the ribonucleotide cleavage reaction, 2 µl protein mix with the indicated components from Apn2, RFC, PCNA, RPA, Exo1, Polδ was added to the reaction and incubated for an additional 10 min at 30 °C. The reaction was stopped by adding 12 µl stopping buffer containing 85% formamide with 0.4% SDS, 25 mM EDTA, and 1 µM unlabeled H1 (ribonucleotide-containing strand). The reaction mixtures were heated at 75 °C for 5 min and resolved in 12% denaturing polyacrylamide gel before being subjected to phosphorimaging analysis.
Statistics and reproducibility. Each experiment was repeated 3-5 times independently with similar results.
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
Phosphorimaging data were collected with Typhoon 5 Biomolecular Imager controlled by ImageQuant TL 8 (GE Healthcare)
Data analysis
Phosphorimaging data were quantified with Image J software. Data plotting was conducted using either Excel or Graphpad Prism.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability Data availability statement included.
